Subodh Verma

MD, FRCSC, FAHA, PhD

Scientist, Keenan Research Centre for Biomedical Science

Biography

Please note: Dr. Verma will not take students in summer.

Dr Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the Canada Research Chair in Cardiovascular Surgery and a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He served as Canada Research Chair in Atherosclerosis for 10 years from 2007-2017. He is an appointee of the
American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar, Dr Verma’s work has been cited nearly 28,000 times resulting in an h-index of 82.

Dr Verma has published numerous times in prestigious journals like the NEJM, Lancet, Circulation, JBC, JACC, Nature, and JCI. He continues to be an active contributor to several CCS guidelines and co-authored the 2018 Diabetes Canada guidelines and 2018 AATS consensus guidelines on bicuspid aortic valve-related aortopathy. Dr Verma has served on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr Verma has leadership roles on 7 ongoing global heart failure trials in diabetes – Dapa-HF, DELIVER, DETERMINE-A, DETERMINE-B, EMPEROR-Preserved, EMPEROR-Reduced and SOLOIST-WHF – as well as the SELECT (semaglutide) and CLEAR SYNERGY (OASIS 9) trials. He oversees the CardioLink platform that is conducting surgically oriented RCTs and translational studies.

Dr Verma oversees a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. This research has yielded 2 United States patents and is currently supported by the Canadian Institutes of Health Research (CIHR) and HSF.

 

Recent Publications

  1. Verma, S, Sharma, A, Zinman, B, Ofstad, AP, Fitchett, D, Brueckmann, M et al.. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2020; :. doi: 10.1111/dom.14015. PubMed PMID:32227432 .
  2. Bhatt, DL, Eikelboom, JW, Connolly, SJ, Steg, PG, Anand, SS, Verma, S et al.. The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial. Circulation. 2020; :. doi: 10.1161/CIRCULATIONAHA.120.046448. PubMed PMID:32223318 .
  3. Docherty, KF, Jhund, PS, Inzucchi, SE, Køber, L, Kosiborod, MN, Martinez, FA et al.. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur. Heart J. 2020; :. doi: 10.1093/eurheartj/ehaa183. PubMed PMID:32221582 .
  4. Petrie, MC, Verma, S, Docherty, KF, Inzucchi, SE, Anand, I, Belohlávek, J et al.. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020; :. doi: 10.1001/jama.2020.1906. PubMed PMID:32219386 .
  5. Salata, K, Abdallah, FW, Hussain, MA, de Mestral, C, Greco, E, Aljabri, B et al.. Short-term outcomes of combined neuraxial and general anaesthesia versus general anaesthesia alone for elective open abdominal aortic aneurysm repair: retrospective population-based cohort study. Br J Anaesth. 2020; :. doi: 10.1016/j.bja.2020.01.018. PubMed PMID:32216957 .
  6. Bami, K, Gandhi, S, Leong-Poi, H, Yan, AT, Ho, E, Zahrani, M et al.. Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. J Am Soc Echocardiogr. 2020; :. doi: 10.1016/j.echo.2020.02.005. PubMed PMID:32199780 .
  7. Lawler, PR, Bhatt, DL, Godoy, LC, Lüscher, TF, Bonow, RO, Verma, S et al.. Targeting cardiovascular inflammation: next steps in clinical translation. Eur. Heart J. 2020; :. doi: 10.1093/eurheartj/ehaa099. PubMed PMID:32176778 .
  8. Opingari, E, Verma, S, Connelly, KA, Mazer, CD, Teoh, H, Quan, A et al.. The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrol. Dial. Transplant. 2020; :. doi: 10.1093/ndt/gfz294. PubMed PMID:32159783 .
  9. Verma, S. Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?. JACC Basic Transl Sci. 2020;5 (2):180-182. doi: 10.1016/j.jacbts.2020.01.011. PubMed PMID:32142070 PubMed Central PMC7046535.
  10. Yanagawa, B, Lee, J, Ouzounian, M, Bagai, A, Cheema, A, Verma, S et al.. Mitral valve prosthesis choice in patients <70 years: A systematic review and meta-analysis of 20 219 patients. J Card Surg. 2020; :. doi: 10.1111/jocs.14478. PubMed PMID:32092191 .
Search PubMed

Affiliations & Other Activities

  • Staff Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor, Department of Surgery and Pharmacology & Toxicology, University of Toronto
X